# US 10,370,349 B2 · Functionalised benzopyran compounds and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,370,349 B2
- Document ID: US10370349B2
- Status: Granted
- Kind: B2
- Application number: 15/613,711
- Filed: 2017-06-05
- Published: 2018-05-24
- Granted: 2019-08-06
- Earliest claimed: 2014-02-07
- Assignees: Kazia Therapeutics Limited
- Applicants: Novogen Limited
- Inventors: Andrew Heaton; David Brown; Graham Kelly
- Web page: https://patentgrep.com/patent/US10370349B2

## CPC

- C07D 311/58: other than with oxygen or sulphur atoms in position 2 or 4
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07D 407/04: directly linked by a ring-member-to-ring-member bond
- C07D 407/10: linked by a carbon chain containing aromatic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Benzopyran compounds, the preparation thereof, and their use in methods for treating cancer and reducing the incidence or risk of cancer recurrence. The cancer can be one or more of pancreatic cancer, colorectal cancer, melanoma, prostate cancer, brain cancer (including paediatric and adult), ovarian cancer, breast cancer, lung cancer, liver cancer, uterine cancer, neuroblastoma, mesothelioma, malignant ascites or peritoneal cancer.

## Claims

### Claim 1

A compound of the general formula (I)
or a pharmaceutically acceptable salt thereof,
wherein R1 is selected from the group consisting of: H and C1-C6 alkyl,
R2 is selected from the group consisting of: OH and C1-C6 alkoxy,
R3 is selected from the group consisting of: H, C1-C6 alkyl, and halo,
R10 to R12 are independently selected from the group consisting of: OH, C1-C6 alkyl, C1-C6 alkoxy, and halo,
R13 and one of R14 and R15 form the following structure:
and
the other one of R14 and R15 is selected from the group consisting of: H, OH, C1-C6 alkyl, and halo.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising the compound of formula (I) according to claim 1 and further comprising a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 3 (depends on 1)

A method for treatment of cancer in a subject in need thereof, the method comprising administration to the subject of a therapeutically effective amount of the compound of formula (I) according to claim 1.

### Claim 4 (depends on 3)

The method of claim 3, wherein the cancer is a cancer that has recurred.

### Claim 5 (depends on 3)

The method of claim 3, wherein the cancer is resistant to one or more chemotherapeutic agents.

### Claim 6 (depends on 3)

The method of claim 3, wherein the cancer is selected from the group consisting of: pancreatic cancer, colorectal cancer, melanoma, prostate cancer, brain cancer (including paediatric and adult), ovarian cancer, breast cancer, lung cancer, liver cancer, uterine cancer, neuroblastoma, mesothelioma, malignant ascites and peritoneal cancer.

### Claim 7 (depends on 1)

A method for reducing incidences of, or risk of, cancer recurrence in a subject deemed to be at risk of cancer recurrence, the method comprising administration to the subject of an effective amount of the compound of formula (I) according to claim 1.

### Claim 8 (depends on 7)

The method of claim 7, wherein the subject deemed to be at risk of cancer recurrence is a subject who is in cancer remission.